Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Low Testosterone Lawsuits Transferred to Federal Multidistrict Litigation in Northern District of Illinois, The Oliver Law Group P.C. Reports
  • USA - English


News provided by

The Oliver Law Group

Jun 18, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Contact the Oliver Law Group P.C. for your FREE testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com.
Contact the Oliver Law Group P.C. for your FREE testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com.

Contact the Oliver Law Group P.C. for your FREE testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com.

Post this

Detroit MI (PRWEB) June 18, 2014 -- The Oliver Law Group P.C. notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) has created a multidistrict litigation in the U.S. District Court, Northern District of Illinois for low testosterone lawsuits that claim drugs like AndroGel, Axiron, Testim, Foresta, AndroDerm and Depo-Testosterone caused men to suffer serious cardiovascular problems, including heart attacks, strokes and sudden death. While the JPML’s June 6th Transfer Order initially sends 49 testosterone lawsuits to the Northern District of Illinois, the Panel noted that dozens of other cases eligible for transfer are currently pending in federal courts around the country. The Order also points out that plaintiffs in low testosterone lawsuits have predicted that the litigation could ultimately involve thousands of cases.
(In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
[ fda.gov/drugs/drugsafety/ucm383904.htm ]
[ fda.gov/downloads/drugs/drugsafety/ucm383909.pdf ]

Multidistrict Litigations For Testosterone Treatment Lawsuits

According to the Oliver Law Group, multidistrict litigations like the one created for testosterone treatment lawsuits allow a large number of claims involving common allegations of fact to progress more efficiently by avoiding duplicative discovery and inconsistent court rulings. Court records indicate that all of the low testosterone lawsuits transferred to the Northern District of Illinois put forth similar allegations regarding the heart side effects potentially associated with testosterone replacement therapies, as well as the marketing tactics used by defendants to drive sales of the drugs.

According to the June 6th Transfer Order, plaintiffs had originally petitioned the JPML to create a multidistrict litigation in Illinois for all federally-filed AndroGel lawsuits. But the Panel opted to grant a defense request to establish an industry-wide proceeding because many of the low testosterone lawsuits filed thus far involve more than one medication. The Northern District of Illinois was chosen for the litigation because a majority of claims were pending in that jurisdiction. U.S. District Judge Matthew F. Kennelly, who has been tapped to oversee the proceeding, had already begun organizing the docket in a coordinated manner.

According to the U.S. Food & Drug Administration (FDA), testosterone replacement gels, patches, pellets and injections are approved to treat low testosterone, also known as hypogonadism, in men who suffer from the condition as a result of an underlying medical disorder, including the side effects of chemotherapy and problems with the hypothalamus gland. The litigation surrounding these products began to mount after the FDA revealed in January that it was reviewing the safety of testosterone replacement drugs after studies suggested they could increase the risk of heart attacks, strokes and death in certain men.
[ fda.gov/drugs/drugsafety/ucm383904.htm ]

Free Low Testosterone Lawsuit Reviews

The Oliver Law Group is offering free low testosterone lawsuit reviews to men who allegedly suffered heart attacks, strokes or other cardiovascular events due to testosterone replacement drugs. Free legal evaluations are also being offered to families of men who allegedly died as result of a testosterone-related heart event. To learn more about filing a testosterone therapy lawsuit, please contact our office by calling 800-939-7878 today.

About The Oliver Law Group P.C.

Oliver Law Group P.C. is a different kind of law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.
Experience. Dedication. Trust. Oliver Law Group P.C.

If you would like to learn more about filing a testosterone lawsuit, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free case review by calling toll free 800-939-7878 today or visit http://www.legalactionnow.com.

Contact:
The Oliver Law Group
(800) 939-7878

950 W University Drive
Suite #200,
Rochester, MI 48307

Facebook
Twitter
Google+

Alyson Oliver, The Oliver Law Group, http://www.legalactionnow.com, +1 800-939-7878, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.